Cargando…

sCD25 as an independent adverse prognostic factor in adult patients with HLH: results of a multicenter retrospective study

Hemophagocytic lymphohistiocytosis (HLH) is a rare but often fatal hyperinflammatory syndrome caused by an inborn or acquired error of immunity. In adults, the underlying immunodeficiency generally arises alongside severe infections, malignancies, autoimmune diseases, and immunosuppressive treatment...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wimmer, Thomas, Mattes, Raphael, Stemmler, Hans-Joachim, Hauck, Fabian, Schulze-Koops, Hendrik, Stecher, Stephanie-Susanne, Starck, Michael, Wendtner, Clemens-Martin, Bojko, Peter, Hentrich, Marcus, Nickel, Katharina E., Götze, Katharina S., Bassermann, Florian, von Bergwelt-Baildon, Michael, Spiekermann, Karsten
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society of Hematology 2022
Materias:	Clinical Trials and Observations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9986715/ https://www.ncbi.nlm.nih.gov/pubmed/35973195 http://dx.doi.org/10.1182/bloodadvances.2022007953

Ejemplares similares

A feasibility randomized controlled trial of an mHealth app vs booklets for patient-facing guidelines in adults with SCD
por: Cronin, Robert M., et al.
Publicado: (2023)

Deferiprone vs deferoxamine for transfusional iron overload in SCD and other anemias: a randomized, open-label noninferiority study
por: Kwiatkowski, Janet L., et al.
Publicado: (2022)

Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in children with SCD: a V114-023 (PNEU-SICKLE) study
por: Quinn, Charles T., et al.
Publicado: (2022)

Der knochenmarktransplantierte Patient auf der Intensivstation
por: Stecher, S.-S., et al.
Publicado: (2021)

Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplications
por: Döhner, Hartmut, et al.
Publicado: (2022)

Vector-based SARS-CoV-2 vaccination is associated with improved T-cell responses in hematological neoplasia
por: Engelmann, Robby, et al.
Publicado: (2023)

Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma
por: Dickinson, Michael, et al.
Publicado: (2021)

Treatment, outcome and re-vaccination of patients with SARS-CoV-2 vaccine-associated immune thrombocytopenia
por: Ruzicka, Michael, et al.
Publicado: (2022)

COVID-19, plasma, and hypogammaglobulinemia
por: Murphy, Michael F., et al.
Publicado: (2020)

Melanoma arising in a giant nevus spilus maculosus
por: Stella, Alexander, et al.
Publicado: (2011)

A survey to evaluate knowledge, perceptions and attitudes toward COVID-19 vaccinations among rheumatologists in Germany
por: Hasseli, Rebecca, et al.
Publicado: (2021)

Economic evaluation of regular transfusions for cerebral infarct recurrence in the Silent Cerebral Infarct Transfusion Trial
por: Hsu, Peter, et al.
Publicado: (2021)

Dabrafenib, alone or in combination with trametinib, in BRAF V600–mutated pediatric Langerhans cell histiocytosis
por: Whitlock, James A., et al.
Publicado: (2023)

Targeting RARA overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AML
por: de Botton, Stéphane, et al.
Publicado: (2022)

Therapy-related myeloid neoplasms in 109 patients after radiation monotherapy
por: Patel, Anand Ashwin, et al.
Publicado: (2021)

Phase 2 study of danicopan in patients with paroxysmal nocturnal hemoglobinuria with an inadequate response to eculizumab
por: Kulasekararaj, Austin G., et al.
Publicado: (2021)

Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation
por: Penter, Livius, et al.
Publicado: (2021)

Tisagenlecleucel immunogenicity in relapsed/refractory acute lymphoblastic leukemia and diffuse large B-cell lymphoma
por: Thudium Mueller, Karen, et al.
Publicado: (2021)

Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma
por: Scordo, Michael, et al.
Publicado: (2023)

Dose-finding study of ibrutinib and venetoclax in relapsed or refractory mantle cell lymphoma
por: Portell, Craig A., et al.
Publicado: (2022)

Recombinant von Willebrand factor prophylaxis in patients with severe von Willebrand disease: phase 3 study results
por: Leebeek, Frank W. G., et al.
Publicado: (2022)

Feasibility trial for the management of severe acute malnutrition in older children with sickle cell anemia in Nigeria
por: Abdullahi, Shehu U., et al.
Publicado: (2023)

Immune restoration with ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia: the phase 2 CAPTIVATE study
por: Moreno, Carol, et al.
Publicado: (2023)

A phase 2 multicenter trial of ofatumumab and prednisone as initial therapy for chronic graft-versus-host disease
por: Lazaryan, Aleksandr, et al.
Publicado: (2022)

Reduced cardiovascular morbidity in patients with hemophilia: results of a 5-year multinational prospective study
por: Van Der Valk, Paul, et al.
Publicado: (2022)

Clinical predictors of poor outcomes in patients with sickle cell disease and COVID-19 infection
por: Minniti, Caterina P., et al.
Publicado: (2021)

Reduced intensity hematopoietic stem cell transplantation for accelerated-phase myelofibrosis
por: Gagelmann, Nico, et al.
Publicado: (2022)

Prophylactic tranexamic acid in patients with hematologic malignancy: a placebo-controlled, randomized clinical trial
por: Gernsheimer, Terry B., et al.
Publicado: (2022)

Zinc for infection prevention in children with sickle cell anemia: a randomized double-blind placebo-controlled trial
por: Namazzi, Ruth, et al.
Publicado: (2023)

Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy
por: Fabrizio, Vanessa A., et al.
Publicado: (2022)

A phase 1 trial utilizing TMI with fludarabine-melphalan in patients with hematologic malignancies undergoing second allo-SCT
por: Tran, Misha C., et al.
Publicado: (2022)

Pharmacodynamics and molecular correlates of response to glofitamab in relapsed/refractory non-Hodgkin lymphoma
por: Bröske, Ann-Marie E., et al.
Publicado: (2022)

Safety and activity of pembrolizumab in combination with rituximab in relapsed or refractory follicular lymphoma
por: Nastoupil, Loretta J., et al.
Publicado: (2022)

More intensive therapy has a better effect for frail parents with multiple myeloma
por: DuMontier, Clark, et al.
Publicado: (2023)

Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma
por: Frigault, Matthew J., et al.
Publicado: (2022)

Hydroxyurea for secondary stroke prevention in children with sickle cell anemia in Nigeria: a randomized controlled trial
por: Abdullahi, Shehu U., et al.
Publicado: (2023)

Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapy
por: Wudhikarn, Kitsada, et al.
Publicado: (2022)

Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma
por: Zinzani, Pier Luigi, et al.
Publicado: (2022)

An MRD-stratified pediatric protocol is as deliverable in adolescents and young adults as in children with ALL
por: Greenwood, Matthew, et al.
Publicado: (2021)

Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial
por: Röth, Alexander, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2e9c3b1askohjdj39fekbadnq9